MST Mid-States

RNS Number:7215T
Mid-States PLC
06 May 2008


                                MID-STATES PLC

 Mid-States and Aerosan Technology Announce Exclusive 5-Year Irish Hospital and
                  Healthcare Distribution Agreement for the AD

Embargoed until 7am 6 May 2008

Mid-States PLC, (LSE:MST), ("Mid-States", the "Company" or the "Group"), a
leading environmental technology group, and Aerosan Technology Limited
("Aerosan"), a member of the same group as ATP, a leading provider of cleansing
products to the Irish healthcare market, are today pleased to announce an
exclusive distribution agreement for Mid-States' ground-breaking air
disinfection device, the AD, covering the hospital and healthcare markets in
Ireland. The agreement also includes provision for on-going maintenance of each
device.

Under the terms of the 5-year agreement, Aerosan has placed an initial bulk
order for AD units from Mid-States. Given that, for optimum performance, each
bay in each hospital ward should have its own AD, there is clearly a significant
market opportunity for this device in Ireland. Demand from Irish hospitals is
expected to be significant and to increase substantially in subsequent years.

The AD is already being successfully used in a number of hospitals in the UK,
including Sunderland Royal Infirmary. Mid-States is pleased to report the first
order under the recently announced Sunlight Services distribution agreement, to
supply Hereford Hospitals NHS Trust.

The AD has been proven to clear enclosed spaces of airborne bacteria and viruses
including MRSA, C. diff and E. coli by producing hydroxyl radicals indoors,
safely reproducing the natural disinfection effect that occurs in fresh air
outdoors.

Mike Heath, Managing Director of Mid-States, commented:

"This is our second strategic distribution agreement for the AD in just three
weeks which demonstrates the ever increasing acceptance of this device as a
highly effective way of combating superbugs in hospitals and elsewhere. We are
delighted to have secured Aerosan as our latest partner to distribute this
important device to hospitals and the rest of the healthcare market in Ireland.
We look forward to working with them to ensure that as many patients as possible
benefit from this ground breaking technology as quickly as possible."

"We are also delighted that Hereford hospitals NHS trust has purchased the AD,
which further confirms the growing interest of hospitals in the AD."

Pat Mahony, Managing Director of Aerosan, said:

"We are delighted to have been selected as Mid-States' distribution partner and
are now in a position to roll out this exceptional product across the healthcare
market in Ireland."

For further information

Mid-States PLC                                  +44 (0) 20 7603 1515
Andrew Tonks, Finance Director

Panmure Gordon (UK) Limited                     +44 (0)20 7459 3600
Andrew Godber
Tom Nicholson

Brunswick Group LLP                             +44 (0)20 7404 5959
Justine McIlroy
Annabel Entress

Notes to Editors:

About Mid-States

   *Mid-States PLC is a leading environmental technology group quoted on the
    Alternative Investment Market (AIM) of the London Stock Exchange. The AD is
    sold by Inov8 Science Limited, a wholly owned subsidiary of Mid-States PLC.

   *Mid-States is supported by an eminent group of scientific advisers,
    including Professor Hugh Pennington, former President of the Society for
    General Microbiology, is the UK's leading authority on identifying and
    combating life-threatening bacteria. Professor Derek Ellwood is a world
    renowned microbiologist who has advised both the United Nations and the
    World Health Organisation on human health and vaccination. Clive Beggs is
    Professor of Medical Technology at the University of Bradford. He is an
    expert in the use of environmental and engineering systems to prevent the
    spread of infectious disease and has an international reputation in this
    field.


About the AD

   *The disinfecting characteristics of the open air were known to Louis
    Pasteur when he began to develop vaccination in the late 1800s and have been
    a source of many dedicated scientific investigations in subsequent years.
    This 'cleansing air' effect was historically thought to be related to
    sunlight.

   *The original work which led to the AD's development was commissioned by
    the British Government in the 1960s. Wary of the potential for night time
    biological attack, government scientists were put to work to unravel the
    secrets of the "Open Air Factor." Although some progress was made, as the
    threat of attack waned, so did the funding for the research.

   *However, a dedicated group of scientists and engineers continued to
    investigate. They proved that this naturally occurring phenomenon was not
    only the key to disinfection in fresh air, but also a key part of the human
    immune system.

   *They identified the "Open Air Factor" is the hydroxyl radical
    (OHdegrees). Hydroxyl radicals are generated in a number of reactions
    essential to life. In the body, hydroxyl radicals are produced by cells to
    kill invading pathogens as an essential part of the body's natural defence
    systems. In the fresh air, hydroxyl radials are produced by the reaction of
    ozone and olefins, the natural scents of flowers and plants.


About Aerosan

   * Aerosan Technology Limited is a member of the same group as ATP

   * ATP is a long established distributor of products to the healthcare
     market in Ireland

   * ATP distributes a range of specialist healthcare cleansing products




                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
AGRFKBKKCBKDAPK

Mid-states (LSE:MST)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024

Mid-states (LSE:MST)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024